Alnylam Pharmaceuticals Stock Probability of Future Stock Price Finishing Under 237.92
| ALNY Stock | USD 245.44 6.57 2.75% |
Alnylam |
Alnylam Pharmaceuticals Target Price Odds to finish below 237.92
The tendency of Alnylam Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to drop to $ 237.92 or more in 90 days |
| 245.44 | 90 days | 237.92 | about 5.09 |
Based on a normal probability distribution, the odds of Alnylam Pharmaceuticals to drop to $ 237.92 or more in 90 days from now is about 5.09 (This Alnylam Pharmaceuticals probability density function shows the probability of Alnylam Stock to fall within a particular range of prices over 90 days) . Probability of Alnylam Pharmaceuticals price to stay between $ 237.92 and its current price of $245.44 at the end of the 90-day period is about 6.35 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.34 . This suggests as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Alnylam Pharmaceuticals will likely underperform. Additionally Alnylam Pharmaceuticals has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial. Alnylam Pharmaceuticals Price Density |
| Price |
Predictive Modules for Alnylam Pharmaceuticals
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Alnylam Pharmaceuticals. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Alnylam Pharmaceuticals Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Alnylam Pharmaceuticals is not an exception. The market had few large corrections towards the Alnylam Pharmaceuticals' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Alnylam Pharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Alnylam Pharmaceuticals within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.2 | |
β | Beta against Dow Jones | 1.34 | |
σ | Overall volatility | 17.48 | |
Ir | Information ratio | -0.09 |
Alnylam Pharmaceuticals Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Alnylam Pharmaceuticals for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Alnylam Pharmaceuticals can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Alnylam Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 1.83 B. Net Loss for the year was (440.24 M) with profit before overhead, payroll, taxes, and interest of 868.6 M. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam |
Alnylam Pharmaceuticals Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Alnylam Stock often depends not only on the future outlook of the current and potential Alnylam Pharmaceuticals' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Alnylam Pharmaceuticals' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 124.9 M | |
| Cash And Short Term Investments | 2.4 B |
Alnylam Pharmaceuticals Technical Analysis
Alnylam Pharmaceuticals' future price can be derived by breaking down and analyzing its technical indicators over time. Alnylam Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Alnylam Pharmaceuticals. In general, you should focus on analyzing Alnylam Stock price patterns and their correlations with different microeconomic environments and drivers.
Alnylam Pharmaceuticals Predictive Forecast Models
Alnylam Pharmaceuticals' time-series forecasting models is one of many Alnylam Pharmaceuticals' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Alnylam Pharmaceuticals' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Alnylam Pharmaceuticals
Checking the ongoing alerts about Alnylam Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Alnylam Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
| Alnylam Pharmaceuticals generated a negative expected return over the last 90 days | |
| The company reported the previous year's revenue of 1.83 B. Net Loss for the year was (440.24 M) with profit before overhead, payroll, taxes, and interest of 868.6 M. | |
| Over 98.0% of the company shares are held by institutions such as insurance companies | |
| Latest headline from finance.yahoo.com: The Zacks Analyst Blog Highlights Sarepta Therapeutics, ADMA Biologics, Exelixis and Alnylam |
Additional Tools for Alnylam Stock Analysis
When running Alnylam Pharmaceuticals' price analysis, check to measure Alnylam Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Alnylam Pharmaceuticals is operating at the current time. Most of Alnylam Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Alnylam Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Alnylam Pharmaceuticals' price. Additionally, you may evaluate how the addition of Alnylam Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.